Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF: IRX-101 vs Povidone-Iodine for Post-Intravitreal Injection Pain
NCT05747430Phase 2Completed
- Sponsor
- iRenix Medical, Inc.
- Start
- Feb 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IRX-101 in corneal epitheliopathy, sponsored by iRenix Medical, Inc.. Started Feb 2023; status: completed.
02
Drugs
IRX-101
03
Conditions
corneal epitheliopathy
Beyond the preview
Go deeper on NCT05747430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747430.